{"entity":{"id":"rejuv-tx-second-cancers","kind":"technology","name":"Second cancers after allogeneic transplant","aka":["solid cancers after HCT","second primary malignancy after transplant","post-transplant malignancy"],"tldr":"People who have had a donor transplant develop new, unrelated cancers about twice as often as people of the same age, and by fifteen years about three times as often. Radiation in the conditioning matters most for those irradiated young, and chronic GvHD raises squamous cancers of skin and mouth. Both point at lifelong screening.","summary":"The largest study of this question followed 28,874 allogeneic transplant recipients and identified 189 solid cancers. Overall, patients developed new solid cancers at twice the rate expected from general population rates, with an observed-to-expected ratio of 2.1 (95 per cent CI 1.8 to 2.5), and the risk increased over time (P for trend less than 0.001), reaching threefold among patients followed for fifteen years or more. The study's new finding concerned age at irradiation: among patients irradiated at ages under 30, the relative risk of non-squamous cancer was nine times that of non-irradiated patients, while for older patients it was 1.1, a highly significant interaction (P less than 0.01). Chronic graft-versus-host disease and male sex were the main determinants of squamous cell carcinoma risk. The authors concluded that the data support strategies to promote lifelong surveillance.\n\nRadiation is not the whole explanation. A second study examined 4,318 recipients of a first allogeneic transplant conditioned with high-dose busulfan and cyclophosphamide, with no total body irradiation, for acute myeloid leukaemia in first remission or chronic myeloid leukaemia in first chronic phase, representing 22,041 person-years. Sixty-six solid cancers were reported at a median of six years. Cumulative incidence at five and ten years was 0.6 and 1.2 per cent for the AML group and 0.9 and 2.4 per cent for the CML group. Compared with general population rates, recipients had a 1.4-fold higher than expected rate of invasive solid cancers (95 per cent CI 1.08 to 1.79, P = 0.01), with significantly elevated risks for tumours of the oral cavity, oesophagus, lung, soft tissue and brain. Chronic graft-versus-host disease was an independent risk factor for all solid cancers and especially for cancers of the oral cavity. The authors' conclusion was that incidence continues to increase with time and lifelong cancer surveillance is warranted.\n\nSo: the excess exists with and without radiation, radiation multiplies it most in those exposed young, and chronic GvHD is a consistent independent risk factor across both studies, concentrated in the squamous epithelium it damages, skin and mouth.\n\nWhat follows practically. Skin examination and mouth examination belong in routine follow-up, and in someone with chronic GvHD the mouth examination is being done for two reasons at once. Sun protection matters for a person on long-term immunosuppression in a way it does not for the general population. Smoking cessation does more here than almost anywhere else in survivorship, given the oral cavity, oesophageal and lung excesses. Population screening programmes should be entered and not skipped, and in some circumstances started earlier, which is a decision for the transplant follow-up team against the published recommendations. And new oral lesions, persistent hoarseness or a skin lesion that is changing should be examined rather than watched.\n\nTherapy-related myeloid neoplasms and post-transplant lymphoproliferative disorder are a different problem with different timing and are not covered here: the second cancers field in adults belongs to another facet of this round, and this record is the transplant-specific part of it.","status":"established","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Secondary_malignant_neoplasm","links":[{"label":"Rizzo et al., Solid cancers after allogeneic hematopoietic cell transplantation (Blood 2009)","url":"https://doi.org/10.1182/blood-2008-05-158782"},{"label":"Majhail et al., Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning (Blood 2011)","url":"https://doi.org/10.1182/blood-2010-07-294629"},{"label":"Majhail et al., Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation (Biol Blood Marrow Transplant 2012)","url":"https://doi.org/10.1016/j.bbmt.2011.12.519"},{"label":"Inamoto and Lee, Late effects of blood and marrow transplantation (Haematologica 2017)","url":"https://doi.org/10.3324/haematol.2016.150250"}],"tags":["rejuvenation","survivorship","transplant","late-effects","second-cancer"],"related":["rejuv-tx-late-effects-overview","rejuv-tx-survival-after-transplant","gvhd-chronic-overview","gvhd-organ-by-organ","rejuv-tx-long-term-follow-up-frameworks","rejuv-age-clonal-haematopoiesis-after-therapy"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":["allogeneic-hsct","total-body-irradiation","survivorship-care-plan"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["secondary-malignancy","late-effects","conditioning-regimen"],"trials":[],"people":[],"bottlenecks":["b-survivorship"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Three mechanisms overlap. Ionising radiation induces DNA damage in tissues outside the marrow, with a latency of a decade or more and a steeper dose-response in tissues that are still growing, which is why age at exposure dominates. Chronic alloimmune inflammation at epithelial surfaces, the same surfaces chronic GvHD injures, promotes squamous carcinogenesis. And prolonged immunosuppression reduces immune surveillance, particularly of virus-associated and cutaneous tumours.","strengths":["Quantified in very large registry cohorts, 28,874 and 4,318 patients","The two main risk factors, radiation exposure at a young age and chronic GvHD, are identifiable in any individual","The commonest excess cancers, skin and oral, are accessible to simple examination","Both studies conclude in favour of lifelong surveillance, so the recommendation is explicit"],"limitations":["Risk rises rather than falls with time since transplant","Absolute numbers are modest, so counselling has to convey a raised relative risk without overstating the absolute one","Cohorts reflect conditioning practice of their era","Surveillance intensity beyond routine population screening is not supported by randomised evidence in this group"]},"route":"/technologies/rejuv-tx-second-cancers/","neighbours":{"technology":[{"id":"rejuv-tx-what-to-ask-for","kind":"technology","name":"After a transplant or cell therapy: what to ask for","route":"/technologies/rejuv-tx-what-to-ask-for/"},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"gvhd-chronic-overview","kind":"technology","name":"Chronic graft-versus-host disease","route":"/technologies/gvhd-chronic-overview/"},{"id":"gvhd-organ-by-organ","kind":"technology","name":"Chronic GvHD organ by organ: skin, mouth, eyes, gut, liver, joints and genital tract","route":"/technologies/gvhd-organ-by-organ/"},{"id":"rejuv-age-clonal-haematopoiesis-after-therapy","kind":"technology","name":"Clonal haematopoiesis after cancer treatment","route":"/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/"},{"id":"rejuv-tx-late-effects-overview","kind":"technology","name":"Late effects after a stem cell transplant","route":"/technologies/rejuv-tx-late-effects-overview/"},{"id":"rejuv-tx-secondary-t-cell-malignancy","kind":"technology","name":"Secondary T-cell malignancy after CAR-T, and what the FDA's 2024 action actually says","route":"/technologies/rejuv-tx-secondary-t-cell-malignancy/"},{"id":"rejuv-tx-survival-after-transplant","kind":"technology","name":"Survival after transplant, and why the curve never quite rejoins the population","route":"/technologies/rejuv-tx-survival-after-transplant/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"},{"id":"total-body-irradiation","kind":"technology","name":"Total body and total marrow irradiation","route":"/technologies/total-body-irradiation/"},{"id":"rejuv-tx-long-term-follow-up-frameworks","kind":"technology","name":"Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered","route":"/technologies/rejuv-tx-long-term-follow-up-frameworks/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"term":[{"id":"conditioning-regimen","kind":"term","name":"Conditioning regimen (myeloablative, reduced-intensity)","route":"/terms/conditioning-regimen/"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/"},{"id":"secondary-malignancy","kind":"term","name":"Secondary malignancy (therapy-related cancer)","route":"/terms/secondary-malignancy/"}],"bottleneck":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"},{"id":"rejuv-agenda-latency-outruns-the-evidence","kind":"bottleneck","name":"The newest treatments have not existed long enough for their late effects to appear","route":"/bottlenecks/rejuv-agenda-latency-outruns-the-evidence/"}]}}